The a4b2 neuronal nicotinic acetylcholine receptor (nAChR) plays a crucial role in nicotine addiction.
I-labeled epibatidine binding assays were performed on Xenopus oocytes to assess agonist activation and receptor expression. When ACh was used as an agonist, a decrease in receptor activation was observed for the majority of the mutations. When nicotine was used as an agonist, four mutations exhibited a statistically significant hypersensitivity to nicotine (S438D, S469A, Y576A, and S589A). Additionally, two mutations (S516D and T536A) that displayed normal activation with ACh displayed remarkable reductions in sensitivity to nicotine. Binding assays revealed a constitutive up-regulation in these two nicotine mutations with reduced nicotine sensitivity.
These results suggest that consensus phosphorylation residues in the M3eM4 cytoplasmic loop of the a4 subunit play a crucial role in regulating a4b2 nAChR agonist selectivity and functional expression.
Furthermore, these results suggest that disruption of specific interactions at PKC putative consensus sites can render a4b2 nAChRs almost insensitive to nicotine without substantial effects on normal AChR function. Therefore, these PKC consensus sites in the M3eM4 cytoplasmic loop of the a4 nAChR subunit could be a target for smoking cessation drugs.
© 2015 Elsevier Ltd. All rights reserved.
Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligandgated ion channels that belong to a gene super family of homologous receptors including g-aminobutyric acid (GABA), glycine, and serotonin receptors. The receptor is composed of five subunits with each having four transmembrane domains (M1eM4) and a large intracellular loop (C2). The genes for the neuronal subunits that have been cloned so far are divided into two subfamilies of nine a (a2ea10) and three b (b2eb4) subunits, and are expressed in the nervous system, cochlea, and a number of non-neuronal tissues (Gotti and Clementi, 2004; Hogg et al., 2003) .
Neuronal nAChRs have a role in the mediation of tolerance and addiction to nicotine in chronic tobacco users and the symptoms of withdrawal experienced upon cessation of use (Benowitz, 1996) . The complex activities of nicotine in the nervous system are due to its ability to mimic the activity of acetylcholine (ACh) on these receptors (Gaimarri et al., 2007) . At the molecular level, chronic nicotine exposure differentially affects the number (up-regulation), subunit composition, stoichiometry, and functional status (desensitization and inactivation) of some nAChR subtypes, leaving others substantially unaffected (Gaimarri et al., 2007) . Nicotine, the Abbreviations: nachr, nicotinic acetylcholine receptor; ACh, acetylcholine; PKA, protein kinase A; PKB, protein kinase B; PKC, protein kinase C; CKII, casein kinase II; TK, tyrosine kinase; HEPES, N-(2-hydroxyethyl)piperazine-N 0 -2-ethanesulfonic acid; CPM, counts per minute.
addictive component of tobacco, has a predominant effect in the brain mainly on the a4b2 nAChR, the most abundant subtype.
Desensitization and up-regulation of nAChRs is thought to involve phosphorylation mediated by various kinases (Fenster et al., 1999b) . For instance, protein kinase A (PKA) (Madhok et al., 1994) and protein kinase C (PKC) (Eilers et al., 1997) are examples of kinases that have been studied in the context of nAChR desensitization and up-regulation. Specifically, studies suggest that in the continuous presence of nicotine, receptors would be driven into inactive/desensitized conformations (Lukas, 1991; Marks et al., 1993; Peng et al., 1994) , a process likely influenced by the level of phosphorylation (Eilers et al., 1997; Gopalakrishnan et al., 1997) . There is evidence that activators of PKA and PKC increase nAChR binding sites and synergistically enhance nicotine-induced receptor up-regulation (Gopalakrishnan et al., 1997) . These findings are validated by in vitro and in vivo studies, which have demonstrated that a4 nAChR subunits are phosphorylated (Hsu et al., 1997; Nakayama et al., 1993a Nakayama et al., , 1993b and, more specifically, that they are targets of PKA phosphorylation (Wecker et al., 2001) . Studies using phosphopeptide mapping have provided evidence that residues S365, S472, and S491 of the rat a4 subunit, corresponding to positions S364, S471 and S490 on the current a4 NCBI reference sequence, are substrates for PKA phosphorylation (Guo and Wecker, 2002) . In addition, a recent study identified two major substrate sites for PKA phosphorylation on the human a4 subunit, namely S467 and S362, which are homologues to rat a4 positions S471 and S364 used in the current study (Pollock et al., 2007) .
Recent work from our laboratory has shown that two point mutations of a PKC phosphorylation residue, S336A and S336D, exhibit constitutive up-regulation when expressed in oocytes (L opez-Hern andez et al., 2009 ). In addition, we found that both of these PKC mutations changed the ACh affinity but exhibited no change in nicotine affinity, suggesting that the properties of agonist binding for a4b2 channel activation have very distinct dynamic and/or structural requirements for ACh and nicotine (L opezHern andez et al., 2009) .
On the basis of these findings, we examined various consensus positions in the M3eM4 cytoplasmic loop of the a4 subunit (Fig. S1) in an attempt to dissect the potential role of this domain in the functional response of the a4b2 nAChR. This domain contains conserved consensus sites for various protein kinases (PKA, PKC, CKII, and TK) (Viseshakul et al., 1998) and has been recently mentioned as a possible target for allosteric sites (Taly et al., 2009) . In the present study, eleven of these sites were mutated, to alanine and aspartic acid, to study the effect of a4 subunit phosphorylation on the a4b2 nAChR activation and expression. The rationale for using alanine and aspartic acid substitutions is that alanine impairs phosphorylation, whereas aspartic acid mimics phosphorylation of the protein (Arany et al., 2013) . We used ACh and nicotine as agonists to test the functionality of the mutations as compared with the wild-type receptor. The present results reveal a novel allosteric linkage between the M3eM4 cytoplasmic loop of the a4 neuronal nAChR subunit that can regulate an agonist's selectivity and functional expression. We suggest that this domain could be considered as a structural target for the development of smoking cessation drugs given that point mutations at this domain can decrease nicotine sensitivity (Taly et al., 2009 ).
Materials and methods

Site-directed mutagenesis
Single point mutations were prepared using the Quickchange™ Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The template used for the PCR reaction was the pGEMHE vector with Rattus norvegicus cDNA coding for the a4 neuronal nAChR subunit.
DNA was purified using a QIAprep spin miniprep kit (Quiagen, Germantown, MD) and then sequenced to confirm the incorporation of each mutation. A total of 11 residues in the cytoplasmic loop of the a4 subunit were chosen to be mutated: S364, T417, S438, S469, S471, S490, S504, S516, T536, Y576, and S589. Each residue was mutated to alanine (A) and aspartic acid (D).
In vitro synthesis of mRNA and oocyte microinjection
Each subunit encoding mRNA was synthesized in vitro from linearized pGEMHE plasmid templates of R. norvegicus cDNA coding for a4 and b2 nAChR subunits using the mMessage mMachine RNA transcription kit (Ambion, Austin, TX). mRNA mixtures of a4 and b2 subunits were prepared at 2 mg:3 mg ratio, and 32.2 nL of this mixture was microinjected into each oocyte. The mRNA mixture was microinjected, using a displacement injector (Drummond Instruments, Broomhall, PA), into stage V and VI oocytes that had been extracted, incubated in collagenase Type 1A (Sigma, St. Louis, MO), and defolliculated by manual dissection. The injected oocytes were incubated at 19 C for 3e4 days in ND-96 medium supplemented with albumin, gentamicin, tetracycline, and theophyline. Electrophysiological experiments were performed after the third or fourth day of mRNA injection.
Electrophysiological characterization of a4b2 nAChRs
Oocytes injected with the mRNA transcripts of a4 and b2 subunits were characterized using a two-electrode voltage clamp. AChand nicotine-induced currents were recorded at 20 C, 3e4 days after mRNA injection, with a GeneClamp 500B Amplifier (Axon Instruments, Foster City, CA). Electrodes were filled with 3M KCl and had a resistance of less than 5 MU. Impaled oocytes in the recording chamber were continuously perfused at a rate of 5 ml/min with MOR-2 buffer (115 mM NaCl, 2.5 mM KCl, 5 mM HEPES, 1 mM Na 2 HPO 4 , 0.2 mM CaCl 2 , 5 mM MgCl 2 , and 0.5 mM EGTA, pH 7.4). All the reagents used were purchased from SigmaeAldrich, Co. (St. Louis, MO). For doseeresponse curves, each oocyte was held at a membrane potential of À70 mV. Membrane currents were digitized using the DigiData 1322A interface (Axon Instruments, Foster City, CA), filtered at 2 kHz during recording. The Clampex 10.0 software running on a Pentium 4-based computer was used for data acquisition. Data analysis was via Prism 3.0 (Graphpad Software, San Diego, CA). Doseeresponse data for the a4b2 combination were collected using seven ACh doses (0.1, 1, 3, 10, 30, 100, and a seventh concentration ranging from 300 to 1000 mM depending on the mutant) and seven nicotine concentrations (0.1, 1, 3, 10, 30, 100, 300 mM). The data were fitted using a one-component sigmoidal 
Determination of potential changes in subunit stoichiometry of a4b2 nAChRs using A-85380
To determine whether the a4b2 mutations a4S469Ab2, a4S471Db2, a4T536Ab2 and a4Y576Ab2 expressed in Xenopus laevis oocytes assemble in the a4(2):b2(3) or the a4(3):b2(2) stoichiometry, we estimated the efficacy of agonist A-85380 when compared to ACh 300 mM. The a4(2):b2(3) stoichiometry was favored by microinjecting a4b2 mRNA in a 1:10 ratio, and the a4(3):b2(2) by microinjecting in a 10:1 ratio. The efficacy of A-85380 in WTa4(2):b2(3) and WTa4(3):b2(2) was determined by comparing the macroscopic current elicited by A-85380 100 nM and ACh 300 mM in oocytes microinjected a4b2 mRNA in 1:10 and 10:1 ratios, respectively. For these experiments, we focused our attention on one mutation from each set (PKA, CKII, PKC, and TK) rather than performing a systematic assessment in all the mutations. In doing so, we selected mutations from each set that displayed interesting functional deviations from the WT to explore the possibility that such changes arose from changes in subunit stoichiometry. Because this work contains quite a lot of data, we were inclined not to probe all mutations, but rather test only a functionally interesting representative from each set. The efficacy of A-85380 in a4S469Ab2, a4S471Db2, a4T536Ab2 and a4Y576Ab2 was determined by comparing the macroscopic current elicited by A-85380 100 nM and ACh 300 mM in oocytes microinjected a4b2 mRNA in 2:3 ratio. The changes in stoichiometry in these four mutants were assessed by comparing the efficacy of A-85380 in each mutant compared to WTa4(2):b2(3) and WTa4(3):b2(2).
Results
Functional effects of mutations at PKA putative phosphorylation
sites in the a4 subunit when using ACh as an agonist
Mutations a4S364A, a4S364D, a4S471D, and a4S490A resulted in receptors with a significant decrease in macroscopic peak current as compared with the wild-type (WT) receptor (Fig. 1 ). Mutations a4S471A and a4S490D resulted in non-functional receptors. Statistical analysis using unpaired t tests showed no significant differences in the ACh EC 50 value between mutations a4S364A, a4S364D, a4S490A, and the WT a4b2 nAChR (2.55 ± 0.08, 2.71 ± 0.05, 1.51 ± 0.08, and 2.33 ± 0.03 mM, respectively). On the other hand, mutation a4S471D exhibited a significant EC 50 increase (i.e. 53.60 ± 0.05 mM) as compared with the WT ACh EC 50 value (Table 1) .
3.2. Functional effects of mutations at PKA putative phosphorylation sites in the a4 subunit when using nicotine as an agonist All of the PKA mutants were studied with the use of nicotine as an agonist. The only mutation that exhibited functional activation by nicotine was a4S471D (Fig. 2) . This mutation exhibited a significant decrease in the macroscopic peak current as compared with that of the WT receptor. The nicotine EC 50 values revealed no difference between the mutation and the WT receptor (Table 1) .
This was a remarkable observation as the a4S471D mutation shows a significant difference in ACh activation as compared with the WT; however, nicotine activation in this mutant was similar to that in the WT receptor. This kind of behavior was previously described in mutations of PKC residue S336 (L opez-Hern andez et al., 2009).
3.3. Effects on nAChR expression of mutations at PKA putative phosphorylation sites in the a4 subunit 125 I-labeled epibatidine binding assays revealed the expression patterns of the various mutations of PKA residues in the a4 subunit (Fig. 1C, right panel) . Statistical analysis using unpaired t tests revealed no significant changes among any of the mutations as compared with the WT nAChR. Although mutation a4S490D did not exhibit any function during the voltage-clamp experiments (Table 1) , it was still subjected to the binding assays which revealed no expression for mutation a4S490D.
3.4. Functional effects of mutations at CKII putative phosphorylation sites in the a4 subunit when using ACh as an agonist Voltage-clamp data analysis revealed significant decreases in the macroscopic peak currents for mutations a4T417D and Table 1 Electrophysiological characterization of a4b2 nAChR mutations reveal different nicotine and ACh sensitivities.
a4S438A (Fig. 3) . On the other hand, mutations a4T417A, a4S438D, and a4S469A showed no change in the macroscopic peak current (Table 1) . At the same time, mutations a4S469D, a4S504A, and a4S504D resulted in non-functional receptors. The ACh EC 50 values for all of the functional mutations of the CKII putative sites a4T417A, a4T417D, a4S438A, a4S438D, and a4S469A resulted in significant increases when compared to the WT nAChR (Table 1) .
3.5. Functional effects of mutations at CKII putative phosphorylation sites in the a4 subunit when using nicotine as an agonist When nicotine was used as agonist, we found that mutations a4S469D, a4S504A, and a4S504D also resulted in non-functional receptors. Although mutation a4S438A produced a functional receptor when ACh was used as agonist, it resulted in a non-functional receptor when nicotine was used as an agonist. Mutations of residue a4T417 exhibited no significant change in macroscopic current when compared with the WT receptor; however, their nicotine EC 50 values decreased significantly (Fig. 4) . These mutations displayed a higher potency for nicotine. Interestingly, mutations a4S438D and a4S469A exhibited significant increases in the macroscopic peak currents (2156 ± 475 and 1552 ± 313 nA, respectively) when compared with the WT receptor (387 ± 66 nA) ( Table 1 ). The nicotine EC 50 value for a4S438D exhibited a significant decrease whereas mutation a4S469A exhibited no change. These results suggest that mutations a4S438D and a4S469A enhance the sensitivity to nicotine.
3.6. Effects on nAChR expression of mutations at CKII putative phosphorylation sites in the a4 subunit 125 I-labeled epibatidine binding assays on mutations of the CKII residues revealed significant decreases in receptor expression for mutations a4T417D, a4S438D, and a4S469A (Fig. 3C, right panel) . On the other hand, mutations a4T417A and a4S438A did not exhibit changes in expression when compared with the WT receptor. More interestingly, three mutations that resulted in non-functional receptors when using ACh and nicotine (a4S469D, a4S504A, and a4S504D) exhibited no change in receptor expression (Fig. 3C right panel, and Table 1 ).
3.7. Functional effects of mutations at PKC putative phosphorylation sites in the a4 subunit when using ACh as an agonist
The alanine substitution at position a4S516 displayed a significant decrease in macroscopic peak current (1027 ± 169 nA) (Fig. 5) .
Mutation a4T536A showed a significant increase in macroscopic peak current (3345 ± 129 nA), whereas mutation a4T536D showed a significant decrease in macroscopic peak current (216 ± 85 nA) when compared with the WT receptor ( Table 1) . Mutation a4S589A displayed a functional receptor with no change in macroscopic peak current (1644 ± 192 nA) when compared with the WT receptor. However, mutating the same residue to aspartic acid, a4S589D, resulted in a non-functional receptor (i.e., no significant current was detected). The five mutations that exhibited functional channels (a4S516A, a4S516D, a4T536A, a4T536D, and a4S589A) exhibited a significant increase in the ACh EC 50 value as compared with the WT receptor (Table 1) .
3.8. Functional effects of mutations at PKC putative phosphorylation sites in the a4 subunit when using nicotine as an agonist We performed voltage-clamp experiments on the mutations of PKC putative sites, this time using nicotine as an agonist. Mutations a4S516A, a4T536D, and a4S589D exhibited no nicotine-induced currents, an unsurprising outcome given that their response to ACh was significantly decreased. However, mutations a4S516D and a4T536A exhibited extremely low nicotine-induced currents (Fig. 6 ).
This was an interesting finding because both of these mutations exhibited either no change (a4S516D) or an increase (a4T536A) in the ACh-induced macroscopic peak current. On the other hand, mutation a4S589A displayed a significant increase in macroscopic peak current, while exhibiting no change in the nicotine EC 50 value (Table 1) .
3.9. Effects on nAChR expression of mutations at PKC putative phosphorylation sites in the a4 subunit The binding assays, using 125 I-labeled epibatidine, to measure receptor expression showed significant increases in receptor expression when compared with the WT receptor. Mutations a4S516D, and a4T536A showed significant increases in receptor expression when compared with the WT a4b2 nAChR (Fig. 5C, right   panel) . These mutations resulted in receptors that are constitutively up-regulated. Mutation a4S589D displayed a behavior similar to that seen previously in mutations a4S504A and a4S504D; it showed no signs of ACh-and nicotine-induced macroscopic currents (Table 1) . However, binding assays revealed no change in receptor expression for mutation a4S589D when compared with the WT receptor (Fig. 5C, right panel) .
Functional effects of mutations of a TK putative
phosphorylation site in the a4 subunit when using ACh as an agonist
The alanine substitution in the TK putative site a4Y576 exhibited a significant increase in the macroscopic peak current (4398 ± 450 nA), and the aspartic acid substitution resulted in a significant decrease in macroscopic peak current (396 ± 65 nA) when compared with the a4b2 nAChR (Fig. 7) . The ACh EC 50 values for a4Y576A (55 ± 8 mM) and for a4Y576D (35 ± 7 mM) increased significantly when compared with the WT receptor, which has an EC 50 value of 2.33 ± 0.03 mM (Table 1) . These increases in ACh EC 50 values have also been seen in other mutations.
3.11. Functional effects of mutations of a TK putative phosphorylation site in the a4 subunit when using nicotine as an agonist Mutation a4Y576A exhibited a significant increase in the macroscopic peak current whereas mutation a4Y576D exhibited no significant nicotine-induced current, resulting in a non-functional channel (Fig. 8) . Since mutation a4Y576D exhibited a significant decrease in the ACh-induced macroscopic peak current, it was not surprising that there was no significant nicotine-induced current.
The nicotine EC 50 value for mutation a4Y576A revealed no significant difference when compared with the WT receptor (Table 1 ).
Our data indicate that mutation a4Y576A exhibits an enhanced sensitivity to nicotine.
Effects on nAChR expression of mutations of TK putative phosphorylation sites in the a4 subunit
The results of the binding assays performed on mutations a4Y576A and a4Y576D revealed that only mutation a4Y576D oocytes expressing the mutations a4T417Ab2, a4T417Db2, a4S438Ab2, a4S438Db2, a4S469Ab2, a4S469Db2, a4S504Ab2, and a4S504Db2 and WT a4b2 nAChRs, shown in fmoles (n ¼ 6e17) (*p < 0.05, ***p < 0.0001).
decreased receptor expression significantly, whereas mutation a4Y576A saw no change in receptor expression when compared with the a4b2 nAChR (Fig. 7C, right panel) .
Discussion
Functional implications of PKA consensus phosphorylation
residues in the a4 subunit: possible inhibitory role for PKA residues PKA mutants that expressed functional receptors displayed significant decreases in macroscopic current, whereas receptor expression was unchanged. These results indicate that assembly of the a4b2 nAChR was unaffected by PKA mutations while receptor function was significantly decreased. Also, when ACh was used in mutation a4S364A, it displayed faster decay rates as compared with WT. This result suggests that a residue far away from the binding site of the a4 subunit can affect agonist association and channel activation and inactivation kinetics via a complex network of allosteric interactions.
The mutant a4S490D resulted in no measurable expression levels suggesting that phosphorylation of this residue shuts down a4b2 nAChR expression completely, by affecting trafficking or assembly. Thus, PKA residues may play an inhibitory role in vivo since the mutations mentioned above resulted in functional inhibition and, in one case, complete shut down of a4b2 nAChR expression. 
Functional implications of CKII consensus phosphorylation
residues in the a4 subunit: possible modulatory role for CKII residues Residues a4T417, a4S438, a4S469, and a4S504 may be phosphorylated by CKII due to their amino acid sequence (Viseshakul et al., 1998 ), but they have not been extensively studied. We found that mutations in two of these positions, namely a4S438D and a4S469A, displayed significant increases in their nicotineinduced functional responses, whereas a4S438A and a4S469D exhibited no functional response to nicotine. These results suggest that a single mutation in the a4 intracellular domain can enhance nicotine sensitivity, and that consensus positions in the M3eM4 intracellular domain can influence the allosteric properties of a4b2. Furthermore, because a4S469A exhibited decreased potency for ACh but retained the same potency for nicotine as the WT receptor further demonstrates that nicotine and ACh have different requirements for channel activation. Since a4S469A exhibited an increase in peak currents to nicotine, this mutation could be a novel model for the study of nicotine tolerance. Interestingly, a4S469A
results from the substitution of only one nucleotide and could, therefore, occur in vivo via a single nucleotide polymorphism (SNP) of CHRNA4 (Kim et al., 2003) .
Functional implications of PKC consensus phosphorylation
residues in the a4 subunit: PKC residues may regulate agonist activation and up-regulation It is known that PKC phosphorylates the a4 subunit (Wecker et al., 2001) , and studies using mutations of residues phosphorylated by PKC have demonstrated how phosphorylation affects receptor desensitization and up-regulation by chronic nicotine a4S516Ab2, a4S516Db2, a4T536Ab2, a4T536Db2, a4S589Ab2, and a4S589Db2 and WT a4b2 nAChRs, shown in fmoles (n ¼ 6e17) (*p < 0.05, **p < 0.005, ***p < 0.0005).
treatment (Fenster et al., 1999a) . Two of the PKC mutations, a4S516D and a4T536A, resulted in an increase in receptor expression; no other kinase residue mutations exhibited this kind of behavior. Moreover, these two mutations exhibited either normal (a4S516D) or increased (a4T536A) functional activation by ACh. However, their response to nicotine was extremely reduced as compared with the WT. Moreover, the peak current elicited by a nicotine concentration found in a chronic smoker (i.e. 0.1 mM) was almost undetected (i.e. 5 nA for a4S516D and 6 nA for a4T536A). This finding is remarkable: two novel mutations, far from the binding site, that can influence agonist activation. These two mutations produced a4b2 nAChRs that can discriminate for nicotine activation without major effects on ACh activation. These mutations could provide a novel perspective for new therapies for smoking cessationdtargeting a residue that can make a4b2 nAChRs insensitive to nicotine without major effects on normal AChR function. At the same time, mutation a4S589A exhibited an enhanced sensitivity to nicotine as evidenced by a significant increase in macroscopic peak current. This result is noteworthy in that the identification of a position along the a4 subunit cytoplasmic loop that influences nicotine sensitivity in the a4b2 receptor suggests that this domain could have a role in the design of novel smoking cessation drugs.
Binding assays revealed no change in receptor expression for mutation a4S589D when compared with WT. This result suggests that a negative charge at this position completely shuts down receptor function, regardless of receptor expression levels.
Functional implications of the TK consensus phosphorylation
residue in the a4 subunit: possible role for regulating nicotine sensitivity and expression
Residue a4Y576 is proposed to be phosphorylated by tyrosine kinase (Viseshakul et al., 1998) . The present data suggest that TK sites may play a role in regulating receptor expression and nicotine Comparison of the nicotine-induced macroscopic peak currents, shown in nA (n ¼ 6e17) (*p < 0.05, ***p < 0.0005).
sensitivity. We base this assumption on the fact that mutation a4Y576A exhibits an increase in the peak current to ACh and nicotine. Mutation a4Y576D exhibits a decrease in the functional activation by ACh, fails to respond to nicotine, and exhibits a decrease in receptor expression. These results suggest that phosphorylation at the a4Y576 consensus position down-regulates both receptor function and expression and support our hypothesis for a 9 . Efficacy of a4b2 agonist A-85380 for stoichiometry determination. Oocytes were injected with a4b2 mRNA at either a ratio of 10:1, 1:10 or 2:3 for WTa4b2, and in a 2:3 ratio for a4 mutants a4S469Ab2, a4S471Db2, a4T536Ab2 and a4Y576Ab2. Currents were measured for 300 mM ACh and 100 nM A-85380. Efficacy was measured as the percent of maximum when compared to ACh. The efficacy was significantly lower in oocytes injected at a ratio of 10:1 than oocytes injected at a ratio of 1:10 (***p < 0.0001). Oocytes injected at a 2:3 ratio show no significant difference from those injected at a 1:10 ratio. The four mutations show no significant difference from the WT injected 2:3 or 1:10 ratio, suggesting that the mutated receptors maintain the 2:3 stoichiometry. role for this TK site in regulating agonist sensitivity and receptor expression.
4.5. Changes in ACh potency in the S469A, S471D, T536A and Y576A mutations does not involve alterations in a4b2 nAChRs subunit stoichiometry
The decrease in potency for ACh exhibited by the majority of the mutations suggests potential changes in a4b2 nAChR stoichiometry. Previous studies have shown that the a4(3):b2(2) stoichiometry has a characteristic lower affinity for ACh whereas the a4(2): b2(3) stoichiometry exhibits a higher affinity for ACh (L opezHern andez et al., 2004; Moroni et al., 2006) . Moreover, evidence suggests that phosphorylation of S467 (S471 in the present study) on free a4 subunits prior to their association with b2 subunits has long-lasting consequences, increasing the stability of the a4 subunits (Pollock et al., 2009) . This increase in stability may result in an enhanced expression of a4b2 in the low affinity a4(3):b2 (2) configuration Nelson et al., 2003) . However, as Fig. 9 suggests, the observed decrease in ACh potency cannot be explained by alterations in the a4(2):b2(3) stoichiometry. The efficacy of agonist A-85380 has been reported to be significantly reduced in the a4(3):b2(2) stoichiometry . The efficacy of A-85380 in a4b2 mutations S469A, S471D, T536A, and Y576A indicate that these are assembled according to the a4(2):b2(3) stoichiometry.
Researchers are mostly in the dark about the structure and functional role of the intracellular domain of the AChR. The present data suggest a role for the cytoplasmic loop of the a4 subunit in a4b2 function, expression, and agonist selectivity. Point mutations at consensus sites of the a4 nAChR subunit have remarkable effects on a4b2 function and expression (Table 1) . More specifically, these mutations affect the activation properties of ACh and nicotine; however, it is difficult to confirm a role for phosphorylation from the mutations' effects alone. Since our data show that targeting residues S516 and T536 can render a4b2 nAChRs almost insensitive to nicotine without major effects on normal AChR function, we propose that PKC could be a feasible target for smoking cessation drugs. Therefore, this study provides the framework for further experiments with membrane-permeant cAMP analogs, antagonists, or other potential modulators of phosphorylation. Alternatively, it is possible that the mutations characterized in this study, besides affecting phosphorylation states, could also disrupt key point-to-point interactions essential for secondary structure and/or signal transduction. Twelve mutant receptors (S471A, S471D, T417A, S438A, S469D, S504A, S504D, S516A, T536D, S589A, S589D, and Y576A) exhibited significant changes in potency for ACh without affecting receptor expression levels.
We previously proposed a model that is consistent with an allosteric site for ACh activation, whereas nicotine activation displayed a biphasic curve (L opez-Hern andez et al., 2004; Vibat et al., 1995) . In the present study, six mutations displaced doseeresponse curves to higher ACh concentrations while displaying WT-like biphasic profiles for nicotine activation. Therefore, all of these mutations produced a negative allosteric effect on ACh activation without affecting the biphasic curve for nicotine activation. Furthermore, three other mutations showed only minor changes in the nicotine profile.
Overall, the effects that we observed in this study are fairly complex, for example, we observed decrease in peak response with both A and D mutations. In this particular case it is very likely that the mutation is not really mimicking a phosphorylation. Nonetheless, these results are consistent with previous reports of biphasic nicotine profiles for a4b2 nAChRs (L opez-Hern andez et al., 2004; Vibat et al., 1995) . Most important, we discovered mutations that can provide novel perspectives for the design of nicotine smoking cessation medications that do not act directly or indirectly on the agonist's binding site. Currently, we are designing a4T536A and a4S516D knock-in mutant constructs for the development of transgenic mouse lines with reduced nicotine sensitivity to be used in future studies (patent pending). Overall, these findings provide a new perspective for developing smoking cessation drugs that can definitely cause changes in the pharmacology of nicotinic receptors.
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